Cellular transplantation began not with the derivatives of embryonic stem cells, but with the transplantation of bone marrow cells. Almost 50 years ago, the first studies on experimental bone marrow transplantation began with an analysis of the survival of animals under total irradiation with the subsequent infusion of hematopoietic cells in the bone marrow.
Obviously, the various proliferative and differentiating potencies of hematopoietic stem cells are due to the peculiarities of their ontogenetic development, since in the process of ontogenesis, even the localization of the main regions of hematopoiesis is changing in man.
Hematopoietic stem cells (HSCs), like mesenchymal progenitor cells, are characterized by multipotency and give rise to cell lines, the final elements of which form blood cells, as well as a number of specialized tissue cells of the immune system.
Regenerative-plastic medicine is based on the realization in the clinic of the totality and pluripotent properties of embryonic and progenitor stem cells, which allow in vitro and in vivo to create predetermined cell lines repopulating damaged tissues and organs of a sick person.
The discovery of embryonic stem cells - arose not accidentally, but appeared on the prepared soil of scientific research in the field of developmental biology. The term "stem cell" was introduced into medicine as far back as 1908 at the congress of the hematological society in Berlin by Alexander Maksimov in connection with hematopoietic cells.
Today, few practitioners are aware of the development of a new direction in the treatment of incurable diseases by traditional and non-traditional medicine. It's about regenerative-plastic medicine, based on the use of the regenerative potential of stem cells.